Certara Announces Update of BaseCase Software, the Company's Value Communication PlatformGlobeNewsWire • 07/08/21
Japan's Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara's Biosimulation Software for Evaluating Regulatory SubmissionsGlobeNewsWire • 06/23/21
Certara to Participate in the William Blair Growth Stock Conference and Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/20/21
Certara Releases New Versions of Its Preeminent Quantitative Systems Pharmacology (QSP) Simulators for Expediting Development of Biologics and Immuno-oncology TherapiesGlobeNewsWire • 05/13/21
Certara, Inc. (CERT) CEO William Feehery on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
Certara Reports First Quarter 2021 Financial Results and Updates Full Year 2021 GuidanceGlobeNewsWire • 05/06/21
Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates EarlierGlobeNewsWire • 05/04/21
Certara to Present at the BofA Securities 2021 Virtual Health Care ConferenceBusiness Wire • 04/30/21
Certara to Report Preliminary First Quarter 2021 Financial Results on May 6, 2021Business Wire • 04/22/21
Certara Adopts TrialAssure ANONYMIZE Solution to Speed Life Science Industry Need to Meet Regulatory Requirements for Data SharingBusiness Wire • 03/16/21
Certara, Inc. (CERT) CEO William Feehery on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/05/21
Certara Reports Preliminary Fourth Quarter and Full Year 2020 Results and Issues Full Year 2021 GuidanceBusiness Wire • 03/04/21
The Year 2020 Marks the 7th Consecutive Year Certara Customers Received 90 Percent of US FDA Novel Drug and Biologic ApprovalsBusiness Wire • 02/25/21
Certara to Report Fourth Quarter and Full Year 2020 Preliminary Financial Results on March 4, 2021Business Wire • 02/17/21
Certara Releases Simcyp™ PBPK Simulator Version 20, Including Newly Expanded Biologics SoftwareBusiness Wire • 01/27/21
Certara Announces Closing of Its Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesBusiness Wire • 12/16/20